Skip to main navigation Skip to search Skip to main content

Dinàmica poblacional i deriva antigènica de Bordetella pertussis i el paper d'altres espècies del gènere Bordetella en l'emergència de la tosferina al segle XXI

Student thesis: Doctoral thesis

Abstract

Whooping cough is an acute infectious disease usually caused by Bordetella pertussis, a gram-negative coccobacillus, with an exclusively human reservoir and high airborne transmissibility. It is characterized by presenting a respiratory picture of intense cough that can often last for weeks or months. Among the possible causes that are involved in the pertussis resurgence, the adaptation of B. pertussis to the immunity conferred by acellular vaccines (DTPa), which were introduced in the late 1990s, as well as the emergence of new species of the genus Bordetella, against which the vaccines used do not confer protection, are some of the most important ones that have be considered. On the one hand, the process of adaptation of B. pertussis to the immunity induced by DTPa has been evidenced by the new populations of B. pertussis that have appeared and have gradually replaced the antigenic variants present in the vaccine, concurrently with its introduction. In this sense, a change in the structure of circulating populations has been observed, reflected by the replacement of the electrophoretic profiles that have circulated within the different vaccine periods. Is remarkable the emergence and subsequent predominance of the MT27 genotype, which has been observed in 79.3% of circulating B. pertussis isolates after the introduction of DTPa. Additionally, in these populations, polymorphisms in the genes encoding the pertussis toxin (ptxA) and its promoter (ptxP), pertactin (prn) and fimbria type 3 (fim3). Thus, the allelic combination ptxA1/prn2/fim3-2, which include different antigenic forms than those contained in DTPa, has been observed as the most prevalent (52.7%) among the isolates that have circulated in our environment after the introduction of this type of vaccine. Additionally, a high prevalence (97.7%) of the type 3 pertussis toxin promoter (ptxP3), which induces an increase in the production of this virulence determinant in these B. pertussis isolates, is found in isolates obtained after the DTPa introduction. Other factor that has evidenced the B. pertussis adaptation is the emergence of pertactin (PRN) negative isolates maintaining its virulence and ability to produce disease. In our study, PRN-negative isolates have accounted for the 27.2% of the total studied isolates. They have been identified only during the period of use of DTPa. In this sense, the emergence and successful dissemination of a cluster of isolates that possess a deletion in the promoter and part of the gene encoding this determinant of virulence (58.1%, prn::del(-292 , 1340)), has evidenced the expansion of most of the B. pertussis isolates that do not express PRN. Thus, the spread of B. pertussis isolates expressing vaccine antigens possessing epitopes not recognized by antibodies generated by the use of DTPa, as well as the loss of expression of these antigens as an important mechanism of adaptation and evasion of immunity conferred by pertussis vaccines, seems to be a mechanism contributing to compromise the vaccine effectiveness. Finally, the description of the emergence of B. holmesii as the causative agent of pertussis, observing a prevalence of this microorganism of 3.9% in 2015 and 8.8% in 2016, shows that its circulation has been able to contribute to the pertussis resurgence. In relation to these, no differences were observed in the clinical-epidemiological characteristics of the cases by B. holmesii and those caused by B. pertussis, nor were there any complications or relapses after its treatment with azithromycin. Accurate diagnosis of the causative agent is crucial to determine the incidence and prevalence of the microbial species involved, to assess its contribution to the epidemiology of whooping cough, to evaluate whether specific antimicrobial drug treatments should be implemented and, in terms of public health, to assess the efficacy of the pertussis vaccine.
Date of Award8 Jul 2021
Original languageCatalan
SupervisorJuan Jose Gonzalez Lopez (Director) & Maria Nieves Larrosa Escartin (Director)

Cite this

'